跳至主要内容
临床试验/NCT01397448
NCT01397448已完成2 期

Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Double-blind Comparative Trial-

Eisai Co., Ltd.0 个研究点目标入组 472 人开始时间: 2011年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
472
主要终点
Cumulative Recurrent Rates of Gastric or Duodenal Ulcers

研究概览

简要总结

The primary objective of this study to evaluate the effect of preventing recurrence of gastric or duodenal ulcers by administering E3810 5 mg or 10 mg tablets once daily or Teprenone 150 mg/day (50 mg three times daily) as a control to patients receiving low-dose aspirin and thereby examine the superiority of E3810 over Teprenone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

E3810 5 mg

Experimental

干预措施: E3810 (Drug)

E3810 10 mg

Experimental

干预措施: E3810 (Drug)

Teprenone 150 mg

Active Comparator

干预措施: Teprenone (Drug)

结局指标

主要结局

Cumulative Recurrent Rates of Gastric or Duodenal Ulcers

时间窗: 24 weeks

Mucosal injuries with a white coat measuring 3 mm in diameter will be diagnosed as ulcers. When ulcer is confirmed by endoscopic examination during the trial, it will be regarded as recurrence of ulcer and the trial will be discontinued for the patient involved.

次要结局

  • Cumulative Incidence of Bleeding Ulcers(24 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验